Anti-FMC63 Antibody | Put Your CD19 CAR-T Therapy Ahead from the Start
Release Date:
2025-07-04 15:15
Product Background Overview
Since its development in the 1980s, the FMC63 antibody has become a core component of chimeric antigen receptor T-cell (CAR-T) therapy. Its successful application in the treatment of B-cell malignancies marks a significant breakthrough in cancer immunotherapy. CD19 is a transmembrane protein specifically expressed on the surface of B cells, involved in B-cell receptor signaling and playing a critical role in B-cell development and malignant transformation. It is expressed in most B-cell malignancies, such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma, making it an ideal therapeutic target.
The FMC63 antibody was generated in 1987 by Australian researchers using mouse hybridoma technology, and its single-chain variable fragment (scFv) exhibits high-affinity binding to CD19. Compared with other anti-CD19 antibodies, such as SJ25C1, FMC63 demonstrates more stable binding kinetics and lower off-target effects, making it the preferred choice for CAR-T cell engineering.
FMC63, a murine monoclonal antibody that targets human CD19, has had its scFv sequence widely incorporated into several commercially available CAR-T products. The anti-idiotypic antibody Anti-FMC63 Antibody, owing to its specific binding to the FMC63 scFv, exhibits low background, high specificity, and exceptional sensitivity, making it a common tool for detecting CAR expression derived from the FMC63 scFv. During CAR-T development, the anti-idiotypic antibody generated against the FMC63 scFv serves as an essential reagent for assessing CAR-T cell expression and positivity rates, enabling precise evaluation of antigen expression levels in CAR-T cells.
The Anti-FMC63 Antibody, independently developed by Shanghai Hycells Biotechnology Co., Ltd., is renowned for its High specificity, high sensitivity Its product advantages lie in its specialized application for monitoring CAR expression via flow cytometry. It can be flexibly paired with various flow cytometry assays by selecting appropriate fluorochromes, offering cost-effectiveness and enhanced efficiency.
Product Advantages of the Anti-FMC63 Antibody
Hycells’ anti-FMC63 antibody possesses Low background, high specificity, and high sensitivity Product advantages.
Product Advantages
1. Low background
Hycells’ anti-FMC63 antibody exhibits low background staining in both cell-based and clinical samples.
2. High specificity
Anti-idiotypic antibodies that specifically recognize and bind to the FMC63 scFv ensure low background during detection, enabling more reliable quantification of FMC63 scFv expression in CAR-T cells.
3. High Sensitivity
The product can accurately detect the CAR-T cell positivity rate even in low-concentration samples, enabling earlier and more precise monitoring of changes in CAR-positive T cells.
Case Study on Sharing CAR Positive Rate Testing Data
The following data was kindly provided by the client. Thank you!
Comparison chart of anti-FMC63 APC fluorescence channel detection for a competing brand overseas
Comparison chart of Hycells’ anti-FMC63 APC fluorescence channel detection
Comparison Chart of Hycells G4S PE Fluorescence Channel Detection
-
In summary, the Hycells anti-FMC63 antibody exhibits more distinct clustering, lower background signal, and a higher positive rate compared with other antibodies.
For more details on Hycells Bio’s Anti-FMC63 antibody products, please contact our sales representative. Alternatively, you can scan the QR code below to apply directly for a free sample of the Anti-FMC63 antibody.
Contact: Mr. Xie 15201775322 。
Applications are welcome.
Long-press the QR code to apply for a trial.
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board